[HTML][HTML] Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition
AS Laino, D Woods, M Vassallo, X Qian… - … for immunotherapy of …, 2020 - ncbi.nlm.nih.gov
Journal for immunotherapy of cancer, 2020•ncbi.nlm.nih.gov
Background Inflammatory mediators, including acute phase reactants and cytokines, have
been reported to be associated with clinical efficacy in patients with melanoma and other
cancers receiving immune checkpoint inhibitors (ICI). Analyses of patient sera from three
large phase II/III randomized ICI trials, one of which included a chemotherapy arm, were
performed to assess whether baseline levels of C-reactive protein (CRP), interleukin-6 (IL-6)
or neutrophil/lymphocyte (N/L) ratios were prognostic or predictive.
been reported to be associated with clinical efficacy in patients with melanoma and other
cancers receiving immune checkpoint inhibitors (ICI). Analyses of patient sera from three
large phase II/III randomized ICI trials, one of which included a chemotherapy arm, were
performed to assess whether baseline levels of C-reactive protein (CRP), interleukin-6 (IL-6)
or neutrophil/lymphocyte (N/L) ratios were prognostic or predictive.
Abstract
Background
Inflammatory mediators, including acute phase reactants and cytokines, have been reported to be associated with clinical efficacy in patients with melanoma and other cancers receiving immune checkpoint inhibitors (ICI). Analyses of patient sera from three large phase II/III randomized ICI trials, one of which included a chemotherapy arm, were performed to assess whether baseline levels of C-reactive protein (CRP), interleukin-6 (IL-6) or neutrophil/lymphocyte (N/L) ratios were prognostic or predictive.
ncbi.nlm.nih.gov